Fig. 6: In vivo immunotherapeutic outcomes by LRT nanomedicine treatments for orthotopic Lewis lung tumor model on C57BL/6 J mice.
a In vivo biodistribution evaluation of LRT nanomedicines. Color bar: radiant efficiency [108 p/sec/cm2/sr/μW/cm2]. Representative images of 3 animals with similar results. b Schematic illustration of the experimental procedure to assess the in vivo growth inhibition effects on tumors. c Representative lung 3-dimensional reconstruction and corresponding CT transverse section images from each group (6 animals) after varied treatments as indicated. Scale bar: 5 mm. d The healthy lung volumes of six animals per group quantized by computational extraction through 3D reconstruction. The Kaplan-Meier survival curves and median survival durations (e), and body weight fluctuation (f) in between of LLC tumor-bearing mice after varied therapy. The data were expressed as means ± SD (N = 6 animals), and p values were calculated using the log-rank test. g Red blood cell (RBC) counts of LLC tumor-bearing mice after three dose administrations of LRT nanomedicines, N = 6 animals. Approximately 10 microliters of blood were collected from the tail-vein on day 5 for the counting. Statistical significances were calculated via unpaired one-sided Student’s t test. Boxplots show the distribution of expression with the center of the box representing the mean, the center line corresponds to the median, upper and lower bounds representing 75% and 25% percentiles, and upper and lower whiskers extending to the largest value no further than 1.5 times interquartile range from bounds of box. Source data are provided as a Source Data file.
